Medicxi Ventures Management’s Aura Biosciences AURA Stock Holding History

Medicxi Ventures Management’s Portfolio AURA Stock Details AURA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$20.3M	Hold	3,039,892	–	–	2.07%	4
2025 Q4	$16.6M	Hold	3,039,892	–	–	1.98%	5
2025 Q3	$18.8M	Hold	3,039,892	–	–	2.52%	5
2025 Q2	$19M	Hold	3,039,892	–	–	4.45%	5
2025 Q1	$17.8M	Hold	3,039,892	–	–	4.07%	5
2024 Q4	$25M	Hold	3,039,892	–	–	4.72%	5
2024 Q3	$27.1M	Hold	3,039,892	–	–	5.12%	4
2024 Q2	$23M	Hold	3,039,892	–	–	6.85%	4
2024 Q1	$23.9M	Hold	3,039,892	–	–	5.31%	5
2023 Q4	$26.9M	Hold	3,039,892	–	–	9.09%	5
2023 Q3	$27.3M	Hold	3,039,892	–	–	8.71%	5
2023 Q2	$37.5M	Hold	3,039,892	–	–	10.52%	5
2023 Q1	$28.2M	Hold	3,039,892	–	–	12.09%	4
2022 Q4	$31.9M	Hold	3,039,892	–	–	13.41%	3
2022 Q3	$55.1M	Hold	3,039,892	–	–	22.93%	2
2022 Q2	$43.1M	Hold	3,039,892	–	–	17.89%	2
2022 Q1	$66.9M	Hold	3,039,892	–	–	18.12%	2
2021 Q4	$51.6M	Buy	+3,039,892	New	+$54.3M	12.92%	2

Other funds holding AURA

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Medicxi Ventures Management's AURA Position: Q1 2026 in Review

Medicxi Ventures Management held its Aura Biosciences (AURA) position steady in Q1 2026 at 3,039,892 shares worth $20.3M. The position accounts for 2.07% of the portfolio, ranked #4.

Medicxi Ventures Management first reported a position in AURA in Q4 2021 and has held it in 18 quarters since. The position peaked at $66.9M in Q1 2022. 126 funds tracked by Wall St. Rank hold AURA as of Q1 2026.

Medicxi Ventures Management held 3,039,892 shares of Aura Biosciences worth $20.3M as of Q1 2026.
Medicxi Ventures Management left its Aura Biosciences share count unchanged in Q1 2026.
Aura Biosciences made up 2.07% of Medicxi Ventures Management's portfolio in Q1 2026, its #4 holding.
Medicxi Ventures Management first reported a position in Aura Biosciences in Q4 2021 and has held it in 18 quarters since.
Medicxi Ventures Management's Aura Biosciences position peaked at $66.9M in Q1 2022.
126 funds tracked by Wall St. Rank held Aura Biosciences as of Q1 2026.

Based on Medicxi Ventures Management's 13F filing for Q1 2026, filed 21 Apr 2026.